Brokerages Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) PT at $49.42

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been given an average rating of “Moderate Buy” by the fourteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $49.4167.

A number of analysts recently commented on the company. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada raised their target price on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th.

NewAmsterdam Pharma Price Performance

NAMS opened at $29.64 on Friday. The business has a 50 day simple moving average of $32.80 and a two-hundred day simple moving average of $32.86. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -16.56 and a beta of 0.08. NewAmsterdam Pharma has a one year low of $21.14 and a one year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million during the quarter. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.78 EPS for the current fiscal year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 40,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $30.20, for a total value of $1,208,000.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $735,460.60. This trade represents a 62.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 12.74% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN grew its stake in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Geode Capital Management LLC raised its holdings in NewAmsterdam Pharma by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after purchasing an additional 437 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after buying an additional 544 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares in the last quarter. Finally, AlphaCentric Advisors LLC grew its position in shares of NewAmsterdam Pharma by 6.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock worth $469,000 after buying an additional 925 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.